GAO Finds Serious Problems with Oversight of Clinical Trials; Draft Guidance on Cell Therapy for Heart Disease; Texas May Require Insurance Coverage of Routine Medical Care for Patients; in Clinical Trials; Hsp90 Inhibitor to Begin Phase I Study; Phase I Trial of Lung Cancer Drug Expanded

首页> 外文期刊>Biotechnology Law Report >GAO Finds Serious Problems with Oversight of Clinical Trials; Draft Guidance on Cell Therapy for Heart Disease; Texas May Require Insurance Coverage of Routine Medical Care for Patients; in Clinical Trials; Hsp90 Inhibitor to Begin Phase I Study; Phase I Trial of Lung Cancer Drug Expanded

【24h】

GAO Finds Serious Problems with Oversight of Clinical Trials; Draft Guidance on Cell Therapy for Heart Disease; Texas May Require Insurance Coverage of Routine Medical Care for Patients; in Clinical Trials; Hsp90 Inhibitor to Begin Phase I Study; Phase I Trial of Lung Cancer Drug Expanded

机译：GAO发现临床试验监督存在严重问题；心脏病细胞治疗指南草案；得克萨斯州可能需要为患者提供常规医疗保险；在临床试验中； Hsp90抑制剂开始第一阶段研究；肺癌药物一期试验扩大

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Biotechnology Law Report》 |2009年第3期|p.342-343|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献

1. A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial) [J] . Kimura Tomoki, Nagata Yasushi, Eba Junko, Japanese journal of clinical oncology. . 2017,第3期

机译：用于比较两种剂量分数立体定向体放射疗法（SBRT）的随机期III试验，用于医学上不可操作的阶段IA非小细胞肺癌或小肺病变临床诊断为原发性肺癌：日本临床肿瘤学群体学习JCOG1408（J-SBRT试验的）
2. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study [J] . Thakur Manish K., Heilbrun Lance K., Sheng Shijie, Investigational new drugs. . 2016,第1期

机译：ganetespib（一种热休克蛋白90 Hsp90）抑制剂在多西他赛预处理的转移性去势抵抗性前列腺癌（CRPC）患者中的II期试验-前列腺癌临床试验联合会（PCCTC）研究
3. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non-Small-Cell Lung Cancer - Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial [J] . Swaminath Anand, Wierzbicki Marcin, Parpia Sameer, Clinical lung cancer . 2017,第2期

机译：加拿大阶段III术语III随机试验对阶段I的常规脓性放射疗法，医学上不可操作的非小细胞肺癌 - 对安大略省临床肿瘤组织（OCOG）-Lustre试验的理由和协议设计
4. Clinical studies of SP1049C, a polymer based anthracycline effective against drug resistant tumors. Results of phase II trial and pivotal phase Ⅲ program in upper gastrointestinal cancer indications [C] . Valery Alakhov Controlled Release Society Annual Meeting and Exposition . 2007

机译：SP1049C的临床研究，一种基于聚合物的蒽环类药物可有效抵抗耐药性肿瘤。上消化道癌适应症的II期试验和关键性III期试验结果
5. Clinical predictive value of pre-clinical cancer models: A study of the predictive value of the in vitro cell line, human xenograft and murine allograft pre-clinical cancer models for phase II clinical trials of cytotoxic cancer drugs [D] . Voskoglou-Nomikos, Theodora 2001

机译：临床前癌症模型的临床预测价值：体外细胞系，人异种移植和小鼠同种异体移植临床前癌症模型对细胞毒性癌症药物II期临床试验的预测价值研究
6. A phase II trial of ganetespib a heat shock protein 90 Hsp90) inhibitor in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study [O] . Manish K. Thakur, Lance K. Heilbrun, Shijie Sheng, -1

机译：ganetespib（一种热休克蛋白90 Hsp90）抑制剂的II期临床试验在多西他赛预处理的转移性去势抵抗性前列腺癌（CRPC）患者中进行-前列腺癌临床试验联盟（PCCTC）研究
7. A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial) [O] . Tomoki Kimura, Yasushi Nagata, Junko Eba, 2017

机译：用于比较两种剂量分数立体定向体放射治疗（SBRT）的随机期III试验IA非小细胞肺癌或小肺病变临床诊断为原发性肺癌：日本临床肿瘤学群体研究JCOG1408（J-SBRT试验）

GAO Finds Serious Problems with Oversight of Clinical Trials; Draft Guidance on Cell Therapy for Heart Disease; Texas May Require Insurance Coverage of Routine Medical Care for Patients; in Clinical Trials; Hsp90 Inhibitor to Begin Phase I Study; Phase I Trial of Lung Cancer Drug Expanded

著录项

相似文献

相关主题

期刊订阅